Inayathullah Mohammed, Tan Aaron, Jeyaraj Rebecca, Lam James, Cho Nam-Joon, Liu Corey W, Manoukian Martin A C, Ashkan Keyoumars, Mahmoudi Morteza, Rajadas Jayakumar
Biomaterials & Advanced Drug Delivery Laboratory (BioADD), Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA; Bioorganic and Neurochemistry Laboratory, Central Leather Research Institute, Adyar, Chennai, Tamilnadu, India; Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA.
Biomaterials & Advanced Drug Delivery Laboratory (BioADD), Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA; UCL Medical School, University College London (UCL), London, UK; University College London Hospitals NHS Foundation Trust, London, UK.
Neuropeptides. 2016 Jun;57:71-83. doi: 10.1016/j.npep.2016.01.011. Epub 2016 Feb 3.
Huntington's disease (HD) is recognized as a currently incurable, inherited neurodegenerative disorder caused by the accumulation of misfolded polyglutamine (polyQ) peptide aggregates in neuronal cells. Yet, the mechanism by which newly formed polyQ chains interact and assemble into toxic oligomeric structures remains a critical, unresolved issue. In order to shed further light on the matter, our group elected to investigate the folding of polyQ peptides - examining glutamine repeat lengths ranging from 3 to 44 residues. To characterize these aggregates we employed a diverse array of technologies, including: nuclear magnetic resonance; circular dichroism; Fourier transform infrared spectroscopy; fluorescence resonance energy transfer (FRET), and atomic force microscopy. The data we obtained suggest that an increase in the number of glutamine repeats above 14 residues results in disordered loop structures, with different repeat lengths demonstrating unique folding characteristics. This differential folding manifests in the formation of distinct nano-sized fibrils, and on this basis, we postulate the idea of 14 polyQ repeats representing a critical loop length for neurotoxicity - a property that we hope may prove amenable to future therapeutic intervention. Furthermore, FRET measurements on aged assemblages indicate an increase in the end-to-end distance of the peptide with time, most probably due to the intermixing of individual peptide strands within the nanofibril. Further insight into this apparent time-dependent reorganization of aggregated polyQ peptides may influence future disease modeling of polyQ-related proteinopathies, in addition to directing novel clinical innovations.
亨廷顿舞蹈症(HD)是一种目前无法治愈的遗传性神经退行性疾病,由错误折叠的聚谷氨酰胺(polyQ)肽聚集体在神经元细胞中积累所致。然而,新形成的聚Q链相互作用并组装成有毒寡聚体结构的机制仍是一个关键的、尚未解决的问题。为了进一步阐明这一问题,我们团队选择研究聚Q肽的折叠情况——检测谷氨酰胺重复长度从3至44个残基的肽段。为了表征这些聚集体,我们采用了多种技术,包括:核磁共振;圆二色性;傅里叶变换红外光谱;荧光共振能量转移(FRET)以及原子力显微镜。我们获得的数据表明,谷氨酰胺重复数超过14个残基时会导致无序的环结构,不同的重复长度表现出独特的折叠特征。这种差异折叠表现为形成不同的纳米级纤维,在此基础上,我们推测14个聚Q重复代表神经毒性的关键环长度——我们希望这一特性将来可能适用于治疗干预。此外,对老化聚集体的FRET测量表明,随着时间推移肽段的端到端距离增加,这很可能是由于纳米纤维内单个肽链的相互混合。除了指导新的临床创新外,对聚Q肽聚集体这种明显的时间依赖性重组的进一步了解可能会影响未来聚Q相关蛋白病的疾病建模。